Dynatronics DYNT 深 沪
等待开盘 03-26 09:30:00 美东时间
0.244
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.244
- 总市值 390.43万
- 52周最高 0.91
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.2012
- 委 比 0.00%
- 总股本 1600.13万
- 历史最高 39.70
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.2012
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dynatronics enters Chapter 7 bankruptcy and liquidation
The latest update is out from Dynatronics ( ($DYNT) ). On January 9, 2026, Dyna...
01-13 05:53
Dynatronics Q1 EPS $(0.03) Up From $(0.09) YoY, Sales $7.024M Down From $7.602M YoY
Dynatronics (OTC:DYNT) reported quarterly losses of $(0.03) per share. This is a 66.67 percent increase over losses of $(0.09) per share from the same period last year. The company reported $7.024 million in sales this
2025-11-19 23:22
Dynatronics Delays Form 10-Q Filing
Dynatronics ( ($DYNT) ) has released a notification of late filing. Dynatronics...
2025-11-18 02:18
Dynatronics Corporation Reports 15.8% Decrease in Fiscal 2025 Net Sales to $27.4 Million
Dynatronics Corporation reported net sales of $27.393 million for the fiscal year ended June 30, 2025, a decrease of $5.141 million or 15.8% compared to $32.534 million in the previous year. Gross pro...
2025-10-14 20:11
Dynatronics Delays Annual Report Filing
Dynatronics ( ($DYNT) ) has released a notification of late filing. Dynatronics...
2025-09-27 02:17
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Dyne Therapeutics Inc. announced the commencement of an underwritten public offering of $200 million of its common stock, with an additional $30 million option for underwriters. The offering is being led by Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities. The final terms will be disclosed in a prospectus supplement filed with the SEC. The company focuses on developing therapies for genetically driven neuromuscular diseases such as my...
2025-06-30 20:05
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
<p>Dyne Therapeutics secures a $275 million senior secured term loan facility with Hercules Capital to advance its DM1 and DMD programs, with $100 million upfront and additional funding tied to milestones. The financing supports clinical and regulatory progress, including potential U.S. Accelerated Approval submissions in 2026 and a first launch in DMD in 2027. Hercules Capital highlights its confidence in Dyne’s leadership and pipeline to addres...
2025-06-30 20:01
Dynatronics Q3 GAAP EPS $(0.13) Up From $(0.17) YoY, Sales $6.15M Down From $7.66M YoY
Dynatronics (OTC:DYNT) reported quarterly losses of $(0.13) per share. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year. The company reported $6.15 million in sales this
2025-05-13 05:42
Dynatronics Appoints Ryan Staats as New COO
An announcement from Dynatronics ( ($DYNT) ) is now available. On May 9, 2025, ...
2025-05-09 20:20
Dynatronics Corporation Appoints Ryan Staats as New Chief Operating Officer
Dynatronics Corporation has announced the appointment of Ryan Staats as its new Chief Operating Officer, effective May 9, 2025. Staats, who is 45 years old, previously served as the Vice President of ...
2025-05-09 20:01
